ArticleTheranostics2022
Genome instability is associated with ethnic differences between Asians and Europeans in hepatocellular carcinoma.
Article in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 10 citations in OpenAlex.
- Analysis of genetic mutation characteristics in 40 Chinese patients with hepatocellular carcinoma.Genes & genomics · 2026Article
- Quality of life in patients with hepatocellular carcinoma: a bibliometric analysis.Discover oncology · 2026Article
- Characterization of Mutational Signatures in Tumors from a Large Chinese Population.Cancer research communications · 2025Article
- Associations between dynamic-contrast enhanced MRI with histopathological features in atypical HCC using spatial co-registration with biopsy.American journal of translational research · 2025Article
- Racial disparities in hepatocellular carcinoma: a TCGA-based gene expression study of Caucasian and Asian populations.Exploration of targeted anti-tumor therapy · 2025Article
- Hepatic Bone Morphogenetic Protein and Activin Membrane-Bound Inhibitor Levels Decline in Hepatitis C but Are Not Associated with Progression of Hepatocellular Carcinoma.Biomedicines · 2024Article
- Tumor phylogeography reveals block-shaped spatial heterogeneity and the mode of evolution in Hepatocellular Carcinoma.Nature communications · 2024Article
- Novel genetic alterations in liver cancer distinguish distinct clinical outcomes and combination immunotherapy responses.Frontiers in pharmacology · 2024Article
- Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinoma.Journal for immunotherapy of cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is one of the deadliest cancer types with diverse etiological factors across the world. Although large scale genomic studies have been conducted in different countries, integrative analysis of HCC genomes and ethnic comparison across cohorts are lacking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.